StreetInsider.com News Articles

Form 4 Natera, Inc. For: Oct 15 Filed by: Rabinowitz Matthew

Fri, 16 Oct 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20261016/27199061.html

Form 144 Natera, Inc. Filed by: Rabinowitz Matthew

Thu, 15 Oct 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20261015/27193628.html

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

Thu, 15 Oct 2026 12:46:00 -0400

Signatera recognized in the Medical & Healthcare category for its transformative impact on cancer care

Natera also named to Fortune’s Future 120, which highlights companies poised to define the next chapter of business and innovation

AUSTIN, Texas--(BUSINESS WIRE)--

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME’s Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.

TIME’s Best Inventions list, published annually, highlights the technologies and breakthroughs

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

Thu, 15 Oct 2026 12:46:00 -0400

Signatera recognized in the Medical & Healthcare category for its transformative impact on cancer care

Natera also named to Fortune’s Future 120, which highlights companies poised to define the next chapter of business and innovation

AUSTIN, Texas--(BUSINESS WIRE)--

TIME’s Best Inventions list, published annually, highlights the technologies and breakthroughs

Natera (NTRA) PT Raised to $480 at TD Cowen

Tue, 13 Oct 2026 09:32:19 -0400

TD Cowen analyst Dan Brennan raised the price target on Natera (NASDAQ: NTRA) to $480.00 (from $340.00) while maintaining a rating.

Natera (NTRA) PT Raised to $435 at Morgan Stanley

Tue, 13 Oct 2026 08:24:36 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on Natera (NASDAQ: NTRA) to $435.00 (from $355.00) while maintaining a Overweight rating.

Natera and TransCode team up on colorectal cancer MRD trial

Tue, 13 Oct 2026 07:30:21 -0400

Natera, Inc. (Nasdaq: NTRA) and TransCode Therapeutics, Inc. (Nasdaq: RNAZ) have announced a collaboration to support patient enrollment in TransCode's Phase 2a clinical trial evaluating TTX-MC138 in colorectal cancer (CRC).

Under the agreement, Natera's Signatera test will be used to identify patients who have completed curative-intent therapy and test positive for molecular residual disease (MRD) with no radiographic evidence of disease. Those patients would be eligible for enrollment in the trial.

TTX-MC138 is designed to inhibit microRNA-10b (miR-10b), a biomarker linked to the emergence and progression of metastatic cancers, including CRC. TransCode describes the candidate as a first-in-class therapeutic targeting MRD-positive patients

Natera and TransCode team up on colorectal cancer MRD trial

Tue, 13 Oct 2026 07:30:21 -0400

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC).

The collaboration will support enrollment for TransCode’s Phase 2a trial evaluating TTX-MC138 in patients with CRC. Patients will be eligible for enrollment if they have completed curative-intent therapy and

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Form 4 Natera, Inc. For: Oct 07 Filed by: Rabinowitz Matthew

Fri, 09 Oct 2026 21:25:00 -0400

si-local-file:///var/storage/secattach/20261009/27172583.html

FDA grants breakthrough device designation to Natera's cancer detection test

Fri, 09 Oct 2026 08:01:39 -0400

Natera, Inc. (NASDAQ: NTRA) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its multi-cancer early detection assay, a blood-based test designed to screen for multiple cancer types.

The designation applies to novel technologies intended to enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. The FDA evaluated data from 12 cancer types, examining the test's sensitivity, specificity, and cancer signal origin performance before granting the designation.

Natera's assay analyzes cell-free DNA in the blood to detect cancer signals. The Breakthrough Devices program is intended to speed up development, assessment, and regulatory review for

FDA grants breakthrough device designation to Natera's cancer detection test

Fri, 09 Oct 2026 08:01:39 -0400

Natera's assay analyzes cell-free DNA in the blood to detect cancer signals. The Breakthrough Devices program is intended to speed up development, assessment, and regulatory review for

FDA grants breakthrough device designation to Natera's cancer detection test

Fri, 09 Oct 2026 08:01:39 -0400

Natera's assay analyzes cell-free DNA in the blood to detect cancer signals. The Breakthrough Devices program is intended to speed up development, assessment, and regulatory review for

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

Fri, 09 Oct 2026 08:00:00 -0400

Designation supports the development of a blood-based assay intended to screen for various cancers

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.

Natera’s MCED assay analyzes cell-free DNA in the blood to screen for multiple cancers. In granting the BDD,

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

Fri, 09 Oct 2026 08:00:00 -0400

Designation supports the development of a blood-based assay intended to screen for various cancers

Natera’s MCED assay analyzes cell-free DNA in the blood to screen for multiple cancers. In granting the BDD,

Natera (NTRA) PT Raised to $458 at Baird

Thu, 08 Oct 2026 07:23:33 -0400

Baird analyst Catherine Ramsey Schulte raised the price target on Natera (NASDAQ: NTRA) to $458.00 (from $376.00) while maintaining a Outperform rating.

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

Wed, 07 Oct 2026 08:00:00 -0400

First patients enrolled in multi-center trial evaluating MRD-guided escalation for patients with advanced melanoma

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health.

The study uses Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, an aggressive form of skin cancer. The current standard of care for these patients is combination immunotherapy until clinical progression. This trial is designed

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

Wed, 07 Oct 2026 08:00:00 -0400

First patients enrolled in multi-center trial evaluating MRD-guided escalation for patients with advanced melanoma

Natera (NTRA) PT Raised to $475 at Barclays

Wed, 07 Oct 2026 03:51:09 -0400

Barclays analyst Luke Sergott raised the price target on Natera (NASDAQ: NTRA) to $475.00 (from $340.00) while maintaining a Overweight rating.

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

Tue, 06 Oct 2026 08:00:00 -0400

Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera’s role in informing personalized care management, including radiotherapy treatments

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera’s first participation at ASTRO and a significant step in demonstrating Signatera’s role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tumor types and treatment settings in

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

Tue, 06 Oct 2026 08:00:00 -0400

Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera’s role in informing personalized care management, including radiotherapy treatments

Citi raises Natera price target to $480, keeps Buy rating

Mon, 05 Oct 2026 16:05:06 -0400

Citi raised its price target on Natera (NASDAQ: NTRA) to $480 from $365, while maintaining a Buy rating on the stock.

The firm's analyst cited ongoing momentum in Natera's Signatera product, along with trends in the company's Women's Health and Organ Health segments, as key areas of focus following a meeting with Natera management.

On Signatera growth, management pointed to a rolling four-quarter average sequential growth as the appropriate assumption, referencing approximately 25,500 versus 34,000 incremental units in the second quarter. The company cited guidelines, sales representative productivity, and clinical evidence as growth drivers.

Regarding operating expenses, Citi noted that research and development